Can a Peptide Serum Reduce Expression Lines? A Placebo-Controlled Clinical Trial

Fifty-five women aged 35–60 with mild to moderate facial fine lines were randomized to apply either the peptide serum or a placebo serum twice daily for 12 weeks. The study was double-blind and IRB-approved. Short-term effects were assessed 15 minutes after the first application. Long-term results were evaluated at Weeks 4, 8, and 12 using dermatologist grading, self-assessment questionnaires, VISIA clinical photography, and 3D PRIMOS CR imaging for objective wrinkle measurement.

Expression lines are among the most common cosmetic concerns, and many people want alternatives to injectable neuromodulators like botulinum toxin. This study provides double-blind, placebo-controlled evidence that a topical peptide serum can meaningfully reduce wrinkles — offering a non-invasive option backed by clinical-grade imaging data rather than just subjective impressions.

Injectable neuromodulators like Botox dominate the anti-wrinkle market, but many consumers want non-invasive alternatives. This trial adds to a growing body of evidence that topical peptide formulations — which mimic the muscle-relaxing action of injectables — can deliver measurable results. As peptide delivery technology improves, topical serums may become a credible first-line option for mild to moderate expression lines.

The study included only 55 female subjects, limiting generalizability to men or larger populations. Specific numerical improvements (percentage reduction in wrinkle depth) were not reported in the abstract. The exact peptide composition of the serum was not disclosed, making it difficult to compare with other peptide products. The 12-week duration, while reasonable, does not address long-term durability of results after discontinuation.